Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
27. Juli 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
12. Juli 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
08. Juni 2022 08:30 ET
|
Allogene Therapeutics, Inc.
RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of...
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
19. Mai 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with CancerFindings Underscore Potential of Allogeneic...
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
09. Mai 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics,...
Allogene Therapeutics Reports First Quarter 2022 Financial Results
04. Mai 2022 16:02 ET
|
Allogene Therapeutics, Inc.
Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses...
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
28. April 2022 08:30 ET
|
Allogene Therapeutics, Inc.
New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif., April 28, 2022 ...
Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
27. April 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
27. April 2022 08:00 ET
|
Allogene Therapeutics, Inc.
ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMABCMA Program Clinical...
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
14. April 2022 08:00 ET
|
Allogene Therapeutics, Inc.
Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, CaliforniaCell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for...